Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUT5 | Q11128 | 1/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | HINT1 | P49773 | 4/20 | 0.52 |
| ▸ | GSK3A | P49840 | 2/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | KRAS | P01116 | 7/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.48 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18521953 | 0.94 | FUT5 (0.52) | FUT5NT5EP2RX3TGM2HINT1 | |
| SCHEMBL18521293 | 0.93 | FUT5 (0.62) | FUT5NT5EP2RX3TGM2HINT1 | |
| SCHEMBL22381693 | 0.93 | FUT5 (0.62) | FUT5NT5EP2RX3TGM2HINT1 | |
| SCHEMBL21759039 | 0.91 | POLB (0.56) | FUT5NT5EP2RX3TGM2P2RY2 | |
| SCHEMBL18521078 | 0.90 | FUT5 (0.69) | FUT5NT5EP2RX3TGM2HINT1 | |
| SCHEMBL22399232 | 0.88 | FUT5 (0.60) | FUT5NT5EP2RX3TGM2HINT1 | |
| SCHEMBL18521067 | 0.87 | FUT5 (0.54) | FUT5NT5EP2RX3TGM2HINT1 | |
| SCHEMBL22399475 | 0.87 | NT5E (0.60) | FUT5NT5EP2RX3TGM2HINT1 | |
| SCHEMBL24239209 | 0.85 | FUT5 (0.58) | FUT5NT5EP2RX3TGM2HINT1 | |
| SCHEMBL18521079 | 0.85 | FUT5 (0.68) | FUT5NT5EP2RX3TGM2HINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | FUT5 4404/4885NT5E 1372/4885P2RX3 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.